What is the price-to-earnings ratio of Globeimmune?
The price-earnings ratio of Globeimmune is currently -7.94.
Globeimmune P/E 2024
Globeimmune P/E
-7.94
Ticker
GBIM
ISIN
US37957B1008
WKN
A1J41J
As of Sep 10, 2024, Globeimmune's P/E ratio was -7.94, a 0% change from the 0 P/E ratio recorded in the previous year.
The Globeimmune P/E history
Globeimmune Aktienanalyse
What does Globeimmune do?
Globeimmune Inc. is a biopharmaceutical company that focuses on the development of immunotherapies for various types of cancer. The company was founded in 1998 in Louisville, Colorado, USA, and went public in 2014. Globeimmune's business model revolves around the use of its patented Tarmogen technology, which aims to activate the immune system against cancer cells. The company has conducted clinical studies for its treatments targeting pancreatic, lung, and prostate cancer. Globeimmune has also formed partnerships with other pharmaceutical companies, including one with Sanko Junyaku in Japan to market its Tarmogen technology in Asia. The company's product range includes various immunotherapies based on the Tarmogen technology, such as GI-4000 for pancreatic cancer, GI-6207 for prostate cancer, and GI-6301 for lung cancer. Globeimmune has achieved success in recent years, including completing a financing round of $15.6 million in 2012 and going public with a $35 million IPO in 2014. Overall, Globeimmune is a promising biopharmaceutical company that focuses on developing effective immunotherapies for cancer patients using its Tarmogen technology, which has the potential to revolutionize cancer treatment and provide patients with effective and gentle therapies. Globeimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Globeimmune's P/E Ratio
The Price to Earnings (P/E) Ratio of Globeimmune is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Globeimmune's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Globeimmune is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Globeimmune’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Globeimmune stock
How has the price-earnings ratio of Globeimmune changed compared to last year?
The price-to-earnings ratio of Globeimmune has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Globeimmune high compared to other companies?
Yes, the price-to-earnings ratio of Globeimmune is high compared to other companies.
How does an increase in the price-earnings ratio of Globeimmune affect the company?
An increase in the price-earnings ratio of Globeimmune would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Globeimmune affect the company?
A decrease in the price-earnings ratio of Globeimmune would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Globeimmune?
Some factors that influence the price-earnings ratio of Globeimmune are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Globeimmune pay?
Over the past 12 months, Globeimmune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Globeimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Globeimmune?
The current dividend yield of Globeimmune is .
When does Globeimmune pay dividends?
Globeimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Globeimmune?
Globeimmune paid dividends every year for the past 0 years.
What is the dividend of Globeimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Globeimmune located?
Globeimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Globeimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Globeimmune from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Globeimmune pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Globeimmune in the year 2023?
In the year 2023, Globeimmune distributed 0 USD as dividends.
In which currency does Globeimmune pay out the dividend?
The dividends of Globeimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Globeimmune
Our stock analysis for Globeimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Globeimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
